This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moudgal, V.
Right arrow Articles by Vazquez, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moudgal, V.
Right arrow Articles by Vazquez, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 767-769, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.767-769.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis

Varsha Moudgal, Tania Little, Dina Boikov, and Jose A. Vazquez*

Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan

Received 13 May 2004/ Returned for modification 5 August 2004/ Accepted 21 October 2004


arrow
ABSTRACT
 
Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.


arrow
TEXT
 
Echinocandins are a new class of synthetic antifungals that act by noncompetitive inhibition of the synthesis of 1,3-ß-D-glucan synthase (16). They have demonstrated clinical efficacy in candidemia, in esophageal candidiasis, and as salvage therapy in invasive aspergillosis (2, 9, 12, 14). The concern with echinocandins, as with any new antimicrobial agent, is the potential for the emergence of drug-resistant organisms. In vitro echinocandin resistance has been described and partially characterized (10). In addition, it appears that resistance may also have some element of cross-resistance to other echinocandins (10). Among the Candida species, Candida parapsilosis has been commonly isolated and shown to be less susceptible in vitro to echinocandins than other Candida species are (5, 7, 11, 13, 17).

Case report. A 51-year-old male was admitted with fever 7 months after aortic valve replacement and aortic repair. His blood cultures were positive for C. parapsilosis. The patient was a poor candidate for surgery and was treated with amphotericin B at 0.7 mg/kg/day and flucytosine at 25 mg/kg every 6 h. After 7 days, he development acute renal insufficiency and his antifungal regimen was changed to simultaneous caspofungin acetate at 50 mg/day intravenously (i.v.) along with fluconazole at 400 mg/day i.v. He improved and cleared the C. parapsilosis from his bloodstream. After completing 6 weeks of this combination therapy, he was discharged on fluconazole at 400 mg/day as lifelong suppressive therapy.

Three months later, he was readmitted with fever and chills and his blood cultures again were found to contain C. parapsilosis (isolate 2, Table 1). Fluconazole was discontinued, and i.v. caspofungin was restarted at 50 mg/day. Despite 10 days of therapy, his blood cultures remained positive. At that time, MICs were determined (Table 1) and on the basis of these, his therapy was changed to amphotericin B lipid complex (Abelcet) at 5 mg/kg/day i.v. After 1 week, he improved and his blood cultures became negative.


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro susceptibilities of serial C. parapsilosis isolatesa

Yeast strains. C. parapsilosis was recovered from six separate blood cultures obtained from the patient on separate occasions. The identity of the C. parapsilosis isolate was confirmed by means of germ tube and chlamydospore formation and the API 32C testing kit (bioMérieux). Quality control isolates were used in every testing batch and included ATCC 20019 (C. parapsilosis), ATCC 6258 (C. krusei), and ATCC 90028 (C. albicans).

In vitro antifungal susceptibility assays. All six C. parapsilosis bloodstream isolates and the three quality control isolates were evaluated by the broth microdilution method in accordance with the National Committee for Clinical Laboratory Standards M27-A2 standard (15). The antifungal agents tested included fluconazole, voriconazole, amphotericin B, micafungin, anidulafungin, and caspofungin.

Electrophoretic karyotyping. Strain delineation (genotyping) of C. parapsilosis was established by electrophoretic karyotyping by contour-clamped homogeneous electric field electrophoresis, a form of pulsed-field gel electrophoresis (19). All gels were analyzed in duplicate to ensure reproducibility, as demonstrated elsewhere (19).

The MICs are shown in Table 1. The initial isolate was susceptible to all of the antifungals tested except micafungin, whose MIC was 8 µg/ml. The remaining isolates were obtained during the patient's second hospitalization. The serial C. parapsilosis isolates all demonstrated cross-resistance to fluconazole (MIC, >64 µg/ml) and voriconazole (MIC, >16 µg/ml). In addition, the isolates also demonstrated an increase in the MICs of micafungin and caspofungin (MIC, >16 µg/ml). Interestingly, the MIC of anidulafungin was essentially unchanged, with an increase from 1.0 to 2.0 µg/ml. The MICs of amphotericin B remained the same throughout the course of the infection at 0.25 to 0.5 µg/ml. The MICs for all sequential isolates were identical.

Genotyping of the C. parapsilosis isolates by the contour-clamped homogeneous electric field method revealed that all six isolates (data not shown) had the same pattern and were thus identical strain types.

The echinocandins are a recently developed class of antifungals with a novel mechanism of action (2, 4). They have potent fungicidal activity against Candida species, including the fluconazole-resistant Candida strains (1, 3, 6, 8, 17, 18). There is minimal data available regarding the development of echinocandin resistance in fungi in the clinical setting (10). The initial investigators evaluated independent spontaneous C. albicans mutants resistant to L-733,560, a synthetic pneumocandin. They found that these mutants exhibited cross-resistance to other 1,3-ß-D-glucan synthase inhibitors. In addition, the daughter strains of the resistant C. albicans mutants had glucan synthase activity that was more resistant to pneumocandins than that of the parent strains. These data seem to suggest that the resistant mutants may have an alteration in glucan synthase leading to cross-resistance among the echinocandin class of antifungals, but not to the azole or polyene class of antifungals.

An additional consideration when using echinocandins should be the fact that the entire class has been found to have less intrinsic in vitro activity against C. parapsilosis and C. guilliermondii than against other pathogenic Candida species (11, 13). Whether this decrease in susceptibility correlates with clinical failure remains to be established.

Our patient presented from the community with C. parapsilosis prosthetic valve endocarditis and is unique for a variety of reasons. First, community-acquired C. parapsilosis fungemia in a non-intravenous drug user is extremely uncommon. Second, the initial C. parapsilosis isolate that was obtained from the patient prior to the initiation of any antifungal therapy already revealed a high MIC of micafungin (8 µg/ml) while remaining susceptible to caspofungin and anidulafungin. This is also the first case describing the development of a secondary multidrug (fluconazole, voriconazole, caspofungin, and micafungin)-resistant isolate of C. parapsilosis during continuous antifungal therapy. Furthermore, despite the high-level resistance to caspofungin and micafungin, the isolates did not demonstrate the same increase in the MIC of anidulafungin (2 µg/ml). Furthermore, the isolates developed resistance to fluconazole, but also to voriconazole, to which the patient was not exposed. This again raises concerns regarding the potential for cross-resistance among azoles such as fluconazole and itraconazole and the newer generation of azoles, such as voriconazole and posaconazole.

Finally, the most significant factor that should have been considered in this case is the fact that the optimal management of this patient should have been surgical removal of the infected prosthetic valve, followed by prolonged antifungal therapy. Prosthetic valve endocarditis due to Candida has been associated with frequent medical treatment failures and high mortality rates.

The observations described in this report raise questions regarding the development, incidence, acquisition, and mechanisms of resistance in Candida. Although the expansion of our antifungal armamentarium is truly exciting, a great many issues remain unclear and the exploration of further avenues of research is necessary to address these concerns while improving our understanding of the various antifungals.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Division of Infectious Diseases, Harper University Hospital, 3990 John R, 5 Hudson, Room 5909, Detroit, MI 48201. Phone: (313) 745-9131. Fax: (313) 993-0302. E-mail: jvazquez{at}med.wayne.edu. Back


arrow
REFERENCES
 
    1
  1. Abu-el Teen, K., M. Ghannoum, and R. J. Stretton. 1989. Effects of sub-inhibitory concentrations of antifungal agents on adherence of Candida spp. to buccal epithelial cells in vitro. Mycoses 32:551-562.[Medline]
    2. 2
  2. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.[Abstract/Free Full Text]
    3. 3
  3. Bachmann, S. P., T. F. Patterson, and J. Lopez-Ribot. 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40:2228-2230.[Abstract/Free Full Text]
    4. 4
  4. Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891.[Free Full Text]
    5. 5
  5. Diekema, D. J., S. A. Messer, R. J. Hollis, R. P. Wenzel, and M. A. Pfaller. 1997. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn. Microbiol. Infect. Dis. 29:147-153.[CrossRef][Medline]
    6. 6
  6. Ernst, E. J., E. E. Roling, C. R. Petzold, D. J. Keele, and M. E. Klepser. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and post antifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.[Abstract/Free Full Text]
    7. 6
  7. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.[Medline]
    8. 7
  8. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10:1545-1558.[CrossRef][Medline]
    9. 8
  9. Keating, G. M., and B. Jarvis. 2002. Caspofungin. Drugs 61:1121-1129.
    10. 9
  10. Koss, T., B. Bagheri, C. Zeana, M. F. Romagnoli, and M. E. Grossman. 2002. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J. Am. Acad. Dermatol. 46:945-947.[CrossRef][Medline]
    11. 10
  11. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.[Abstract]
    12. 11
  12. Laverdiere, M., C. Restieri, and F. Habel. 2002. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents 20:468-471.[CrossRef][Medline]
    13. 12
  13. Maertens, J., I. Raad, G. Petrikkos, D. Selleslag, F. Petersen, C. Sable, N. Kartsonis, A. Ngai, A. Taylor, T. Patterson, D. Denning, and T. Walsh. 2002. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, abstr. M-868, p. 388. American Society for Microbiology, Washington, D.C.
    14. 13
  14. Moore, C. B., K. L. Oakley, and D. W. Denning. 2001. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin. Microbiol. Infect. 7:11-16.[CrossRef]
    15. 14
  15. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.[Abstract/Free Full Text]
    16. 15
  16. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    17. 16
  17. Onishi, J., M. Meinz, J. Thompson, J. Curotto, S. Dreikorn, M. Rosenbach, C. Douglas, G. Abruzzo, A. Flattery, L. Kong, A. Cabello, F. Vicente, F. Pelaez, M. T. Diez, I. Martin, G. Bills, R. Giacobbe, A. Dombrowski, R. Schwartz, S. Morris, G. Harris, A. Tsipouras, K. Wilson, and M. B. Kurtz. 2000. Discovery of novel antifungal (1,3)-ß-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 44:368-377.[Abstract/Free Full Text]
    18. 17
  18. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, and R. J. Hollis. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.[Abstract/Free Full Text]
    19. 18
  19. Stone, E. A., H. B. Fung, and H. L. Kirschenbaum. 2002. Caspofungin: an echinocandin antifungal agent. Clin. Ther. 24:351-377.[CrossRef][Medline]
    20. 19
  20. Vazquez, J. A., A. Beckley, S. Donabedian, J. D. Sobel, and M. J. Zervos. 1993. Comparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. J. Clin. Microbiol. 31:2021-2030.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, February 2005, p. 767-769, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.767-769.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sucher, A. J, Chahine, E. B, Balcer, H. E (2009). Echinocandins: The Newest Class of Antifungals. The Annals of Pharmacotherapy 43: 1647-1657 [Abstract] [Full Text]  
  • Silva, A. P., Miranda, I. M., Lisboa, C., Pina-Vaz, C., Rodrigues, A. G. (2009). Prevalence, Distribution, and Antifungal Susceptibility Profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a Tertiary Care Hospital. J. Clin. Microbiol. 47: 2392-2397 [Abstract] [Full Text]  
  • Kitamura, A., Someya, K., Hata, M., Nakajima, R., Takemura, M. (2009). Discovery of a Small-Molecule Inhibitor of {beta}-1,6-Glucan Synthesis. Antimicrob. Agents Chemother. 53: 670-677 [Abstract] [Full Text]  
  • Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., Lee, S. A. (2008). Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52: 4145-4148 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E. (2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098 [Abstract] [Full Text]  
  • Gafter-Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., Paul, M. (2008). Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis. Mayo Clin Proc. 83: 1011-1021 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2008). Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis. J. Clin. Microbiol. 46: 2659-2664 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
  • Pai, M. P., Samples, M. L., Mercier, R.-C., Spilde, M. N. (2008). Activities and Ultrastructural Effects of Antifungal Combinations against Simulated Candida Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 2367-2376 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Dromer, F., Dannaoui, E. (2008). Detection of Caspofungin Resistance in Candida spp. by Etest. J. Clin. Microbiol. 46: 2389-2392 [Abstract] [Full Text]  
  • Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., Ramani, R. (2008). Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. J. Clin. Microbiol. 46: 2155-2159 [Abstract] [Full Text]  
  • Cleary, J. D., Garcia-Effron, G., Chapman, S. W., Perlin, D. S. (2008). Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment. Antimicrob. Agents Chemother. 52: 2263-2265 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2008). Caspofungin Disk Diffusion Breakpoints and Quality Control. J. Clin. Microbiol. 46: 1927-1929 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A., Finquelievich, J., Barnes, R., Wadula, J., the Global Antifungal Surveillance Group, (2008). Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46: 842-849 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Dannaoui, E., Lortholary, O., Raoux, D., Bougnoux, M. E., Galeazzi, G., Lawrence, C., Moissenet, D., Poilane, I., Hoinard, D., Dromer, F., and the YEASTS Group, (2008). Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52: 778-781 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150-156 [Abstract] [Full Text]  
  • Pasquale, T., Tomada, J. R., Ghannoun, M., Dipersio, J., Bonilla, H. (2008). Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 61: 219-219 [Full Text]  
  • Chamilos, G., Lewis, R. E., Albert, N., Kontoyiannis, D. P. (2007). Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences. Antimicrob. Agents Chemother. 51: 2257-2259 [Abstract] [Full Text]  
  • Baixench, M.-T., Aoun, N., Desnos-Ollivier, M., Garcia-Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., Dannaoui, E. (2007). Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59: 1076-1083 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods.. J. Clin. Microbiol. 44: 3533-3538 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1.. Am J Health Syst Pharm 63: 1693-1703 [Abstract] [Full Text]  
  • Bennett, J. E. (2006). Echinocandins for Candidemia in Adults without Neutropenia. NEJM 355: 1154-1159 [Full Text]  
  • Katiyar, S., Pfaller, M., Edlind, T. (2006). Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 2892-2894 [Abstract] [Full Text]  
  • Hakki, M., Staab, J. F., Marr, K. A. (2006). Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy.. Antimicrob. Agents Chemother. 50: 2522-2524 [Abstract] [Full Text]  
  • Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., Cannon, R. D. (2006). Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 1148-1155 [Abstract] [Full Text]  
  • Laverdiere, M., Lalonde, R. G., Baril, J.-G., Sheppard, D. C., Park, S., Perlin, D. S. (2006). Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57: 705-708 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance.. J. Clin. Microbiol. 44: 760-763 [Abstract] [Full Text]  
  • Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006). Inhibition of Candida parapsilosis Mitochondrial Respiratory Pathways Enhances Susceptibility to Caspofungin. Antimicrob. Agents Chemother. 50: 744-747 [Abstract] [Full Text]  
  • Magill, S. S., Shields, C., Sears, C. L., Choti, M., Merz, W. G. (2006). Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy. J. Clin. Microbiol. 44: 529-535 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moudgal, V.
Right arrow Articles by Vazquez, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moudgal, V.
Right arrow Articles by Vazquez, J. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»